Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: Arrest of bone loss

Annals of the Rheumatic Diseases

Volumn 68, Issue 3, 2009, Pages 373-376

  Wijbrandts, C A ^a   Klaasen, R ^a   Dijkgraaf, M G W ^a   Gerlag, D M ^a   Van Eck Smit, B L F ^a   Tak, P P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; METHOTREXATE; PREDNISONE; VITAMIN D;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEMUR NECK; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; LUMBAR SPINE; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE DENSITY; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; FEMALE; FEMUR NECK; GLUCOCORTICOIDS; HUMANS; LUMBAR VERTEBRAE; MALE; METHOTREXATE; MIDDLE AGED; OSTEOPOROSIS; PREDNISONE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61449164945     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.091611     Document Type: Article

References (13)

1. Haugeberg G, Orstavik RE, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. Arthritis Rheum 2002;46:1720-8.
2. Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997;99:1699-703.
3. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001;98:13960-5.
4. Saidenberg-Kermanac'h N, Corrado A, Lemeiter D, deVernejoul MC, Boissier MC, Cohen-Solal ME. TNF-α antibodies and osteoprotegerln decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 2004;35:1200-7.
5. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1495-9.
6. Vis M, Wolbink GJ, Lodder MC, Kostense PJ, van de Stadt RJ, de Koning MH, et al. Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum 2003;48:2996-7.
7. van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999;26:705-11.
8. Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005;44:1546-8.
9. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 2007;9:R61.
10. Allall F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor a. Ann Rheum Dis 2003;62:347-9.
11. Gough AK, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23-7.
12. ørstavik RE, Haugeberg G, Mowinckel P, Høiseth A, Uhlig T, Falch JA. Vertebral deformities in rheumatoid arthritis: a comparison with populationbased controls. Arch Intern Med 2004;164:420-5.
13. Haugeberg G, Strand A, Kvien TK, Kirwan JR. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med 2005;165: 1293-7.